Loading…
FDA User Fee Corrections Act of 2012
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
66pct
16d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (11)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2012 · third_quarter · Health Issues
Patient Protection and Affordable Care Act implementation. Prescription Drug User Fee Act reauthorization. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152 The Healthcare & Education Affordability Reconciliation Act of 2010--issues regarding CER, prescription importation, biosimilars, Physician Payment Sunshine implementation. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "track and trace" issues. H.R. 1513 / S. 810, Great Ape Protection and Cost Savings Act of 2011.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Product exclusivity issues. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 1513 / S. 810, Great Ape Protection and Cost Savings Act of 2011.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
Patient Protection and Affordable Care Act implementation. Prescription Drug User Fee Act reauthorization. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Drug issues; FDA-DEA issues. Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. "Track and trace" legislation. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012. H.R. 1513 / S. 810, Great Ape Protection and Cost Savings Act of 2011.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Antibiotic resistance issues. Pay-for-delay proposals and generic issues. H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011. Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012. H.R. 6433, FDA User Fee Corrections Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Diabetes drugs issues. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "Track and trace" issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (PCAST) H.R. 6433, FDA User Fee Corrections Act H.R. 1513, S. 810, Great Ape Protection & Cost Savings Act of 2011
Client expense: $370,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · fourth_quarter · Health Issues
H.R. 6433: FDA USER FEE CORRECTIONS ACT OF 2012; ALL PROVISIONS OF THE BILL IMPLEMENTATION OF PATIENT PROTECTION AND AFFORDABLE CARE ACT REAUTHORIZATION OF PRESCRIPTION DRUG USER FEE ACT DISCUSSIONS REGARDING ACCESS TO MEDICINE PROGRAM
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
2012 · fourth_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
Antibiotic resistance issues in the following bills Pay-for-delay proposals and generic issues H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011 Prescription Drug User Fee Act Reauthorization H.R. 5651, Food and Drug Administration Reform Act of 2012 S. 2516, Food and Drug Administration Safety and Innovation Act S. 3187, Food and Drug Administration Safety and Innovation Act S. 2292, Patients' FDA Act S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012 H.R. 6433, FDA User Fee Corrections Act of 2012 H.R. 8, American Taxpayer Relief Act of 2012
Client expense: $340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
Prescription Drug User Fee Act reauthorization. Biosimilar products. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Budget/Appropriations
Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Budget/Appropriations
FY 2014 Budget, FY 2013 Budget, Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY12 Presidential Budget Request, FY12 and FY13 Budget H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 H.J.RES.117 - Continuing Appropriations Resolution, 2013 H.RES.778 - Providing for consideration of the joint resolution (H.J. Res. 117) making continuing appropriations for fiscal year 2013 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act
Client expense: $486,262 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Medicare/Medicaid
FY 2014 Budget, FY 2013 Budget, Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Average Manufacture Price (AMP)/AMP Publication, and generic drugs H.R. 3342 - Affordable Medicines Utilization Act of 2011 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 1356 - Affordable Medicines Utilization Act of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $486,262 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Pharmacy
FY 2014 Budget, FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R. 3839 - Drug Shortage Prevention Act of 2012 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 H.R.6584 - Verifying Authority and Legality In Drug Compounding Act of 2012 H.R.6611 - Patient Access to Drugs in Shortage Act of 2012 H.R.6638 - S.A.F.E. Compounded Drugs Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 296 and H.R.2245 Preserving Access to Life-Saving Medication Act S. 373 Fair Prescription Drug Competition Act S. 1584 - Drug Safety and Accountability Act of 2011 S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 2295 - Patient Safety and Generic Labeling Improvement Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $486,262 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Health Issues
H.R. 8 American Taxpayer Relief Act of 2012 H.R. 5979 Medicaid Accountabilty and Care Act H.R. 6433 FDA User Fee Corrections Act of 2012 S.3684 - Senior Navigation and Planning Act H.R.6626 - Health Care Innovation and the Marketplace Technologies Act of 2012 H.R. 6482 Preventive Health Savings Act of 2012 S. 3414 Cybersecurity Act of 2012
Client expense: $120,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · fourth_quarter · Health Issues
Health Care issues specifically related to Group Purchasing Organizations. Issues related to drug shortages. S.3187 Food and Drug Administration Safety and Innovation Act; H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Consumer Issues/Safety/Products
Prescription drug user fee act and other issues related to generic drugs; Generic Drug User Fee Act, S.3187 Food and Drug Administration Safety and Innovation Act, S.2295 the Patient Safety and Generic Labeling Improvement Act, issues related to patent settlements; H.R.6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
Prescription drug user fee act and other issues related to generic drugs; Generic Drug User Fee Act, S.3187 Food and Drug Administration Safety and Innovation Act; S.2295 the Patient Safety and Generic Labeling Improvement Act, issues related to patent settlements; H.R.6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152 The Healthcare & Education Affordability Reconciliation Act of 2010--issues regarding CER, prescription importation, biosimilars, Physician Payment Sunshine implementation. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "track and trace" issues.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Budget/Appropriations
Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY12 Presidential Budget Request, FY12 and FY13 Budget H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 H.J.RES.117 - Continuing Appropriations Resolution, 2013 H.RES.778 - Providing for consideration of the joint resolution (H.J. Res. 117) making continuing appropriations for fiscal year 2013 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act
Client expense: $487,850 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Medicare/Medicaid
FY 2012 Budget, Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Average Manufacture Price (AMP)/AMP Publication, and generic drugs H.R. 3342 - Affordable Medicines Utilization Act of 2011 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 1356 - Affordable Medicines Utilization Act of 2011 S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $487,850 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Pharmacy
FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R. 3839 - Drug Shortage Prevention Act of 2012 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 296 and H.R.2245 Preserving Access to Life-Saving Medication Act S. 373 Fair Prescription Drug Competition Act S. 1584 - Drug Safety and Accountability Act of 2011 S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 2295 - Patient Safety and Generic Labeling Improvement Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $487,850 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Health Issues
H.R. 6433: FDA USER FEE CORRECTIONS ACT OF 2012; ALL PROVISIONS OF THE BILL IMPLEMENTATION OF PATIENT PROTECTION AND AFFORDABLE CARE ACT REAUTHORIZATION OF PRESCRIPTION DRUG USER FEE ACT
Client expense: $730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
S 1884 (School Access to Emergency Epinephrine); HR 6433 FDA User Fee Correction Act; Patent settlements; Serialization; Issues related to HIV/AIDS: Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues related to biogenerics; Issues related to the generic drug industry
Client expense: $453,520 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152 The Healthcare & Education Affordability Reconciliation Act of 2010--issues regarding CER, prescription importation, biosimilars, Physician Payment Sunshine implementation. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "track and trace" issues.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
H.R. 6433: FDA USER FEE CORRECTIONS ACT OF 2012; ALL PROVISIONS OF THE BILL IMPLEMENTATION OF PATIENT PROTECTION AND AFFORDABLE CARE ACT REAUTHORIZATION OF PRESCRIPTION DRUG USER FEE ACT
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Product exclusivity issues. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Patient Protection and Affordable Care Act implementation. Prescription Drug User Fee Act reauthorization. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Drug issues; FDA-DEA issues. Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. "Track and trace" legislation. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Antibiotic resistance issues. Pay-for-delay proposals and generic issues. H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011. Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee Act reauthorization. Diabetes drugs issues. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "Track and trace" issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Prescription Drug User Fee Act reauthorization. Biosimilar products. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $90,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Budget/Appropriations
Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $90,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Prescription Drug User Fee reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S.2516, Food and Drug Administration Safety and Innovation Act. S.3187, Food and Drug Administration Safety and Innovation Act. S.2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
Antibiotic resistance issues. Pay-for-delay proposals and generic issues. H.R. 2182/ S. 1734, Generating Antibiotic Incentives Now Act of 2011-incentives for development of products to treat antibiotic-resistant infections Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Adminitration Reform Act of 2012 - incentives for development of products to treat antibiotic-resistant infections S. 2516, Food and Drug Administration Safety and Innovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act.- incentives for development of products to treat antibiotic-resistant infections S. 2292, Patients' FDA Act S. 2289, Better Pharmaceuticals and Devices for Childrens Act of 2012 H.R. 6433, FDA User Fee Corrections Act of 2012
Client expense: $340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Health Care issues specifically related to Group Purchasing Organizations. Issues related to drug shortages. S.3187 Food and Drug Administration Safety and Innovation Act; H.R. 6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Consumer Issues/Safety/Products
Prescription drug user fee act and other issues related to generic drugs; Generic Drug User Fee Act, S.3187 Food and Drug Administration Safety and Innovation Act, S.2295 the Patient Safety and Generic Labeling Improvement Act, issues related to patent settlements; H.R.6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Prescription drug user fee act and other issues related to generic drugs; Generic Drug User Fee Act, S.3187 Food and Drug Administration Safety and Innovation Act; S.2295 the Patient Safety and Generic Labeling Improvement Act, issues related to patent settlements; H.R.6433, FDA User Fee Corrections Act of 2012.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
Drug Pedigree; Drug Shortages; Generic Drug Labeling; Generic Drugs; HR3026 Safeguarding America's Pharmaceutical Act of 2011; HR4223 Safe Doses Act; S1002 Safe Doses Act; HR5651 FDA Reform Act of 2012; S3187 FDA Safety and Innovation Act; HR6433 FDA User Fee Corrections Act of 2012; HR3590 Patient Protection and Affordable Health Care Act provisions relating to biosimilar medicines; S2295 Patient Safety and Generic Labeling Improvement Act
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
H.R. 6433, the "FDA User Fee Corrections Act of 2012," which amends the Food and Drug Administration Safety and Innovation Act (Public Law 112-144) to make technical changes to both the generic drug user fee program and the medical device user fee program; Monitoring the impact of sequestration on FDA funding Monitoring supply chain safety
Client expense: Not reported · Firm income: $51,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE